Repositioning Candidate Details
| Candidate ID: | R0405 |
| Source ID: | DB02300 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Calcipotriol |
| Synonyms: | |
| Molecular Formula: | C27H40O3 |
| SMILES: | O[C@H](\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)C1CC1 |
| Structure: |
|
| DrugBank Description: | Calcipotriol (INN) or calcipotriene (USAN) is a sythetic derivative of calcitriol or Vitamin D. |
| CAS Number: | 112965-21-6 |
| Molecular Weight: | 412.6047 |
| DrugBank Indication: | For the treatment of moderate plaque psoriasis in adults. |
| DrugBank Pharmacology: | Calcipotriene is a synthetic analog of vitamin D. In humans, the natural supply of vitamin D depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol to vitamin D3 (cholecalciferol) in the skin. |
| DrugBank MoA: | The precise mechanism of calcipotriol in remitting psoriasis is not well-understood, however, it has been shown to have comparable affinity with calcitriol for the Vitamin D receptor while being less than 1% the activity in regulating calcium metabolism. The Vitamin D receptor (VDR) belongs to the steroid/thyroid receptor superfamily, and is found on the cells of many different tissues including the thyroid, bone, kindney, and T cells of the immune system. T cells are known to play a role in psoriasis and are believed to undergo modulation of gene expression with binding of calcipotriol to the VDR. This modulation is thought to affect gene products related to cell differentiation and proliferation. |
| Targets: | Vitamin D3 receptor |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|